Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and immunogenicity of travel vaccines given with MenACWY-CRM in healthy adults
2011-000475-14Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of menacwy conjugate vaccine in meningococcal disease, typhoid fever, yellow fever and 2 more (6 arms), sponsored by Novartis. Primary endpoints: Seroprotection rate for typhoid Vi polysaccharide vaccine and Seroprotection rate for yellow fever vaccine. Started Jun 2011; status: completed.
02
Drugs
menacwy conjugate vaccine
03
Conditions
meningococcal diseasetyphoid feveryellow feverJapanese encephalitis (JE)rabies
Beyond the preview
Go deeper on 2011-000475-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000475-14.